Rheumatoid arthritis

Breakthroughs in Kexing Biopharm's Overseas Efforts: Qualification of Two Licensed Products for GMP Audits in Egypt

Retrieved on: 
Tuesday, April 2, 2024
Ulcerative colitis, Psoriasis, Rheumatoid arthritis, Growth, Ankylosing spondylitis, Drug, EDA, Ageing, Kingdom Holding Company, Crohn's disease, Lung cancer, GMP, Bevacizumab, Infliximab, Pharmaceutical industry

In 2022, Kexing Biopharm secured agreements with 24 overseas market customers and commenced the submission of local drug access registration documents.

Key Points: 
  • In 2022, Kexing Biopharm secured agreements with 24 overseas market customers and commenced the submission of local drug access registration documents.
  • The product underwent GMP audits in Egypt, Brazil, and Indonesia respectively in September 2023, February 2024, and March 2024.
  • In 2022, Kexing Biopharm swiftly reached agreements with 23 overseas market customers, initiating the submission of drug access registration documents.
  • By establishing local subsidiaries, Kexing Biopharm strives to accelerate product registration processes and enhance competitiveness in overseas markets.

Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences

Retrieved on: 
Tuesday, April 2, 2024
Therapy, Patient, SAN, Gilead Sciences, Research, Rheumatoid arthritis, Cancer, IRAK4, Inflammation, Pharmaceutical industry

SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Gilead Sciences has elected to extend the research term of the companies’ ongoing collaboration, originally established in 2019, by an additional two years.

Key Points: 
  • “Gilead’s extension of the research period of this agreement is a testament to the productivity of our collaboration to date.
  • Most importantly, it increases the opportunity for additional clinical candidates and associated milestones to emerge from our work together with the Gilead team,” said Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix.
  • Gilead has an option to license drug candidates resulting from the work, and Nurix retains co-development and co-detail options on up to two programs in the United States, subject to certain restrictions.
  • Upon signing the agreement in 2019, Gilead made an upfront payment of $45.0 million.

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart

Retrieved on: 
Tuesday, April 2, 2024
Janus, Week, CD154, Rheumatoid arthritis, Jaki, Patient, Cohort, KNSA, Joint, Clinical trial, C-reactive protein, CD40, Least squares, Pharmacokinetics, Safety, FDA, Rheumatoid factor, Pharmaceutical industry

HAMILTON, Bermuda, April 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced plans to initiate a Phase 2b trial with abiprubart in Sjogren’s Disease. Additionally, the company announced data from Cohort 4 of the Phase 2 clinical trial of abiprubart in rheumatoid arthritis. Abiprubart is an investigational humanized anti-CD40 monoclonal antibody designed to inhibit CD40-CD154 (CD40 ligand) interaction.

Key Points: 
  • HAMILTON, Bermuda, April 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced plans to initiate a Phase 2b trial with abiprubart in Sjogren’s Disease.
  • Additionally, the company announced data from Cohort 4 of the Phase 2 clinical trial of abiprubart in rheumatoid arthritis.
  • Abiprubart is an investigational humanized anti-CD40 monoclonal antibody designed to inhibit CD40-CD154 (CD40 ligand) interaction.
  • “We believe abiprubart has the potential to provide meaningful benefit to patients suffering from Sjogren’s Disease, a debilitating disorder with no current FDA-approved therapies.

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Retrieved on: 
Thursday, March 28, 2024
Mustang, Rheumatoid arthritis, Rituximab, Chronic lymphocytic leukemia, Patient, DSM-IV codes, CD20, Cancer, Translation, NHL, B cell, Clinical trial, Society, Waldenström macroglobulinemia, Hematology, Health, Lymphoma, Waldenström, Autoimmune disease, Pharmaceutical industry

WORCESTER, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced its expansion into autoimmune diseases with MB-106, a personalized CD20-targeted, 3rd-generation autologous CAR T-cell therapy. MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center (“Fred Hutch”). Mustang and Fred Hutch are in preliminary discussions to explore a potential Phase 1 investigator-sponsored clinical trial to evaluate MB-106 for the treatment of autoimmune diseases.

Key Points: 
  • MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center (“Fred Hutch”).
  • Mustang and Fred Hutch are in preliminary discussions to explore a potential Phase 1 investigator-sponsored clinical trial to evaluate MB-106 for the treatment of autoimmune diseases.
  • “MB-106’s observed safety profile, encouraging efficacy data, and our robust manufacturing capabilities have the potential to translate to improved outcomes for patients with autoimmune diseases.
  • Several antibody therapies targeting CD20 on B-cells have successfully transitioned from cancer to autoimmune diseases, such as rituximab for both lymphoma and rheumatoid arthritis.

China Medical System （867.HK）2023 Annual Results: Despite of the Temporary Financial Performance Pressure Fresh Catalysts Emerged from Successive Innovation Breakthroughs

Retrieved on: 
Thursday, March 28, 2024
Sclerotherapy, RMB, Conditional sentence, NDA, IND, Creativity, Small RNA, Marketing, Gastroenterology, Central nervous system, FIC, City, BIC, CMS, NRDL, Injection, Dermatology, CDMO, Commercialization, Tablet, Pharmacy, Methotrexate, Hospital, Acquisition, Gonadotropin-releasing hormone, RCT, VBP, Rheumatoid arthritis, Growth, Varicose veins, Ecosystem, Blue, Government, Ophthalmology

SHENZHEN, CHINA, March 27, 2024 (GLOBE NEWSWIRE) -- On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results.

Key Points: 
  • SHENZHEN, CHINA, March 27, 2024 (GLOBE NEWSWIRE) -- On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results.
  • Based on above, CMS has successfully entered into its “New Period” of innovation and internationalization development.
  • 4 innovative drugs have started large-scale clinical application, unveiling CMS’s first year of commercialization era of innovative drugs.
  • Under its compliant and efficient commercialization system, the Company's innovative products and exclusive drugs will grow steadily.

ASSERTIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Assertio Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, March 28, 2024
Rheumatoid arthritis, Learning, EPS, Risk, Telephone, Patient, Suppository, Sale, Acquisition, News, ASRT, Complaint, Adjustment, P.C, Spectrum, Spectrum Pharmaceuticals, FDA, Food, Cryptocurrency

Our investigation concerns whether the board of directors of Assertio have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Assertio have breached their fiduciary duties to the company.
  • Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • One of the Company's primary pharmaceutical products is Indocin, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis.
  • Then, on November 8, 2023, Assertio issued a press release announcing its financial results for its third quarter ("Q3") of 2023.

Pair of Digital Health Research Papers Coauthored by Analysis Group Demonstrate Promises of Wearables to Generate Reliable Site-Less Patient-Reported Outcomes in Rheumatoid Arthritis

Retrieved on: 
Tuesday, April 9, 2024
Yee, Aiden, Principal, Observational study, Scientific Reports, Apple, Rheumatoid arthritis, Digital, University, GSK, Bias, Patient, PRO, Research, Nature, Hamy, Analysis Group, Apple Watch, Creagh, Pain, Machine learning, Fatigue

This technology enables clinicians to develop more sensitive and patient-centric endpoints in RA clinical trials and real-world studies.

Key Points: 
  • This technology enables clinicians to develop more sensitive and patient-centric endpoints in RA clinical trials and real-world studies.
  • "Digital health technologies and machine learning augment patient reported outcomes to remotely characterise rheumatoid arthritis," published in February by Nature's npj Digital Medicine (Creagh, A.P., et al.
  • "Digital health technologies and machine learning augment patient reported outcomes to remotely characterise rheumatoid arthritis."
  • "Patient-centric assessment of rheumatoid arthritis using a smartwatch and bespoke mobile app in a clinical setting."

Global Elbow Replacement Market to surpass $200.4 million by 2031, at a CAGR of 4.2%, says Coherent Market Insights

Retrieved on: 
Monday, April 8, 2024
Longevity, Rheumatoid arthritis, Prevalence, Partnership, Patient, AAOS, Elbow, Polyethylene, American Academy, Acquisition, Motion, Quality of life, Injury, Integra, Shoulder, Metal, Partial, Key, Pain, Osteoarthritis, USD, Collection, Plumbing

Elbow replacement surgery is a medical procedure that involves replacing a damaged or diseased elbow joint with an artificial implant.

Key Points: 
  • Elbow replacement surgery is a medical procedure that involves replacing a damaged or diseased elbow joint with an artificial implant.
  • As per the market research report, the elbow replacement market was valued at USD 144.2 million in 2023, with a projected CAGR of 4.2% during the forecast period 2024-2031.
  • Buy this Complete Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/6663
    In terms of type, the elbow replacement market is segmented into partial elbow replacement and total elbow replacement.
  • Partial elbow replacement is expected to dominate the market, owing to its less invasive nature and shorter recovery time compared to total elbow replacement.

Global Elbow Replacement Market to surpass $200.4 million by 2031, at a CAGR of 4.2%, says Coherent Market Insights

Retrieved on: 
Monday, April 8, 2024
Longevity, Rheumatoid arthritis, Prevalence, Partnership, Patient, AAOS, Elbow, Polyethylene, American Academy, Acquisition, Motion, Quality of life, Injury, Integra, Shoulder, Metal, Partial, Key, Pain, Osteoarthritis, USD, Collection, Plumbing

Elbow replacement surgery is a medical procedure that involves replacing a damaged or diseased elbow joint with an artificial implant.

Key Points: 
  • Elbow replacement surgery is a medical procedure that involves replacing a damaged or diseased elbow joint with an artificial implant.
  • As per the market research report, the elbow replacement market was valued at USD 144.2 million in 2023, with a projected CAGR of 4.2% during the forecast period 2024-2031.
  • Buy this Complete Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/6663
    In terms of type, the elbow replacement market is segmented into partial elbow replacement and total elbow replacement.
  • Partial elbow replacement is expected to dominate the market, owing to its less invasive nature and shorter recovery time compared to total elbow replacement.

Infectious Disease Specialist Calls Campaign against Repurposed Drugs in COVID-19 a ‘Great Hypocrisy’

Retrieved on: 
Thursday, March 21, 2024
Vanderbilt University, COVID, HCQ, Rheumatoid arthritis, Infection, Azithromycin, Lupus, Diabetes, COVID-19, Patient, Knowledge, Journal, Mortality, Addiction, Hydroxychloroquine, AAPS, Dysautonomia, Physician, Ivermectin, IVM, Pharmaceutical industry

Just before the death-knell announcement, Dr. Hoffman notes, substantial evidence favoring early use of HCQ had been submitted for publication by Dr. Harvey Risch of Yale.

Key Points: 
  • Just before the death-knell announcement, Dr. Hoffman notes, substantial evidence favoring early use of HCQ had been submitted for publication by Dr. Harvey Risch of Yale.
  • “In fact, all evidence is inherently flawed.”
    Dr. Hoffman points out how inconsistencies and double standards reveal the FDA’s hypocrisy regarding HCQ and ivermectin (IVM).
  • Paxlovid, he writes, has not been shown to be effective in hospitalized COVID patients, whereas the “flawed” study of HCQ demonstrated a greater than 60 percent benefit in reducing mortality.
  • “There is in fact a corpus of knowledge about the use of HCQ, IVM, and other off-label drugs, for example, at c19hcq.org, c19IVM.org18, and earlycovidcare.org,” Dr. Hoffman states.